While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > REGULATORY
REGULATORY
- PAFSC Committee OKs Plan to Monitor Early Safety Signals from Xocova Using MID-NET
December 5, 2022
- LDP Committee Underscores Critical Situation of Drugs in Off-Year Discussions
December 5, 2022
- NHI-Market Price Gap Narrowed, but Chuikyo Payer Reps Say Normal Revision Possible
December 5, 2022
- LDP Project Team Submits Proposal, Calls for Limiting Off-Year Coverage to Drugs with Larger-than-Average Price Gap
December 5, 2022
- Japan Enacts Bill to Amend Infectious Disease Act
December 5, 2022
- Japan Enacts FY2022 Extra Budget, Reserves Nearly 4 Trillion Yen for COVID Response, Medical DX, Childcare
December 5, 2022
- Industry Hews to “No” to Off-Year Plan, but Wants Special Steps If It Is to Happen: LDP Confab
December 2, 2022
- Finance Minister Says Wants to “Reduce People’s Burdens” via Drug Price Revision
December 2, 2022
- Average NHI-Market Price Gap for 2023 Off-Year Revision at 7.0%: MHLW
December 2, 2022
- Japan Plans to Lower Minimum Age for Moderna COVID Booster to 12
December 2, 2022
- Evusheld Shelf Life Extended for 6 Months in Japan
December 1, 2022
- MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
November 30, 2022
- Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
November 29, 2022
- Limit Coverage of Off-Year Re-Pricing to Drugs with Large-than-Average Price Gap: LDP Proposal
November 29, 2022
- Sanofi’s Cemiplimab Backed for Approval, Third PD-1 Inhibitor in Japan
November 29, 2022
- MHLW to Report Responses to Zolgensma Paper Retraction on Dec. 12
November 29, 2022
- MHLW Panel Endorses Teikoku’s Donepezil Tape for Alzheimer’s and More Drugs
November 28, 2022
- LDP Lawmakers’ League Holds Hearing on SaMD Review Status
November 28, 2022
- Japan to Begin Xocova Supply on Nov. 28 ahead of Schedule
November 28, 2022
- MHLW Panel OKs 111 More Health Damage Claims for COVID-19 Vaccines
November 28, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…